XORTX Therapeutics, Inc.

CVE:XRTX ISIN:CA98420Q3061

XORTX Therapeutics, Inc. (NASDAQ:XRTX) (CVE:XRTX) is a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Our focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.

We possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.

 
 
   

View in Other Languages

News

Money Talk Radio with Ellis Martin: XORTX Therapeutics Inc. (NASDAQ:XRTX) (CVE:XRTX) Dr. Allen Davidoff-Look for More M&As in the Kidney Disease Remediation Space in the Future

🕔4/22/2024 9:30:31 AM 690

In this segment of Money Talk Radio with Ellis Martin, we speak with Dr. Allen Davidoff, CEO of XORTX Therapeutics (NASDAQ:XRTX) (CVE:XRTX), a pioneer in developing new therapies for progressive kidney disease and diabetes.

Read Full Article

MONEY TALK RADIO with XORTX Therapeutics Inc. (NASDAQ:XRTX) Dr. Allen Davidoff Explains Advanced Drug Therapy for Kidney Disease and Diabetes

🕔3/3/2024 12:51:21 PM 2735

This is Money Talk Radio with Ellis Martin. Today we're going to take a deep dive into a publicly traded NASDAQ company developing innovative therapies to improve the quality of life of patients with progressive kidney disease as well as diabetes.

Read Full Article
###

1,373 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 103) (Last 30 Days: 195) (Since Published: 500) 

Company Data

    Headquarters
  • 3710 – 33rd Street NW
    Calgary, Alberta T2L 2M1
    Canada
  • Telephone
  • +1-403-455-7727 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.xortx.com/
  • E:
  • info@xortx.com